Compare Quest Diagnostics Inc (DGX) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Global X Lithium & Battery Tech ETF trades at $71.22. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Global X Lithium & Battery Tech ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| DGX | LIT | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.02 | $91.62 |
52-Week Low | $166.42 | $39.73 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
LIT trades at $70.24, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure. The stock has doubled over the past year, driven by strong EV and semiconductor demand. Recent news highlights global EV sales growth, particularly in Europe and China, supporting the lithium and battery technology sector. A dividend of $0.32 is scheduled for July 2026.
Outlook remains positive due to structural demand for lithium in energy storage and EVs, though risks include Chinese export controls and U.S. regulatory uncertainty. Analyst sentiment is mixed, with some highlighting momentum catalysts while technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
